CLINICALTRIALS.GOV REGISTRATION OF LUPUZOR™ PIVOTAL PHASE III TRIAL
TERM SHEET SIGNED WITH US INVESTOR TO SECURE UP TO
ImmuPharma has also signed a Term Sheet with a US investor for a proposed private placement to fund the clinical trial. The initial instalment of funding consists of a convertible loan of
Lupuzor™ (active name Rigerimod, also known as IPP-201101 and P140), is ImmuPharma's lead compound for the treatment of Lupus, (Systemic Lupus Erythematosus or "SLE"), a chronic, potentially life-threatening autoimmune disease. LupuzorTM has been granted Fast Track status by the US FDA and approved to start Phase III trials under a Special Protocol Assessment (SPA) due to its strong safety and efficacy profile. Simbec-Orion, a leading full service international
Since the commencement of work with Simbec-Orion, a number of key and necessary steps have been undertaken including detailed technical feasibility, site selection as well as completion of the regulatory process in each selected country where the trials will be conducted. Key European and US sites have now been identified and it is anticipated that about 15 sites in the US and 20 sites in Europe will be enrolled. Recruitment could be completed during the summer of 2016. Patient dosing is expected to commence this autumn.
Further updates on progress will be provided in due course.
ENDS
For further information please contact:
|
+ 44 (0) 20 7152 4080 |
Dimitri Dimitriou, Chief Executive Officer |
|
Dr Robert Zimmer, President and Chief Scientific Officer |
|
Lisa Baderoon, Head of Investor Relations
|
+ 44 (0) 7721 413496 |
|
|
|
+44 (0) 20 7886 2500 |
Hugh Morgan Fred Walsh Duncan Monteith
|
|
This information is provided by RNS